Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Leukemia

Leukemia, Lymphoid

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

All Drugs and Chemicals

Antineoplastic Agents

Immunomodulating Agents

Tisagenlecleucel

Participants who have undergone standard of care tisagenlecleucel therapy, Participants will received a questionnaire study using patient reported outcomes.

Patients enrolled in ARM B will be asked to participate in the biological sample collection. Participants will received a questionnaire

Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.

Questionnaire for patients receiving therapy

Khanh Nguyen

Liora Schultz, M.D

To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

Participant will take part in a one-time questionnaire to address CAR specific questions.

WECARE survey, consists of questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language)

Surveys will be administered at a single time point post-CAR

Overall survival was the duration from the start of study treatment to death.

probability of recurrence or progression of in patients

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy	NCT05865301	Lymphoid Leukem...	Questionnaire f...	- 26 Years	Stanford University
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy	NCT05865301	Lymphoid Leukem...	Questionnaire f...	- 26 Years	Stanford University
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy	NCT05865301	Lymphoid Leukem...	Questionnaire f...	- 26 Years	Stanford University

Spots Global Cancer Trial Database for questionnaire for patients receiving therapy